<HashMap><database>biostudies-literature</database><scores/><additional><submitter>DEFINE-FLAIR Trial Investigators</submitter><funding>Medical Research Council</funding><funding>National Institute for Health Research (NIHR)</funding><pagination>857-864</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6646975</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>4(9)</volume><pubmed_abstract>&lt;h4>Importance&lt;/h4>Invasive physiologic indices such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are used in clinical practice. Nevertheless, comparative prognostic outcomes of iFR-guided and FFR-guided treatment in patients with type 2 diabetes have not yet been fully investigated.&lt;h4>Objective&lt;/h4>To compare 1-year clinical outcomes of iFR-guided or FFR-guided treatment in patients with and without diabetes in the Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularization (DEFINE-FLAIR) trial.&lt;h4>Design, setting, and participants&lt;/h4>The DEFINE-FLAIR trial is a multicenter, international, randomized, double-blinded trial that randomly assigned 2492 patients in a 1:1 ratio to undergo either iFR-guided or FFR-guided coronary revascularizat</pubmed_abstract><journal>JAMA cardiology</journal><pubmed_title>Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial.</pubmed_title><pmcid>PMC6646975</pmcid><funding_grant_id>G1100443</funding_grant_id><funding_grant_id>ACF-2010-21-008</funding_grant_id><funding_grant_id>CL-2015-21-001</funding_grant_id><pubmed_authors>Matsuo H</pubmed_authors><pubmed_authors>Sezer M</pubmed_authors><pubmed_authors>Baptista SB</pubmed_authors><pubmed_authors>Vinhas H</pubmed_authors><pubmed_authors>Janssens L</pubmed_authors><pubmed_authors>Samuels B</pubmed_authors><pubmed_authors>Malik IS</pubmed_authors><pubmed_authors>DEFINE-FLAIR Trial Investigators</pubmed_authors><pubmed_authors>Singh J</pubmed_authors><pubmed_authors>Petraco R</pubmed_authors><pubmed_authors>Nijjer SS</pubmed_authors><pubmed_authors>Sapontis J</pubmed_authors><pubmed_authors>Lee JM</pubmed_authors><pubmed_authors>Mejia-Renteria H</pubmed_authors><pubmed_authors>van Royen N</pubmed_authors><pubmed_authors>Erglis A</pubmed_authors><pubmed_authors>Sharp ASP</pubmed_authors><pubmed_authors>Krackhardt F</pubmed_authors><pubmed_authors>Shin ES</pubmed_authors><pubmed_authors>Alghamdi A</pubmed_authors><pubmed_authors>Van Belle E</pubmed_authors><pubmed_authors>Sen S</pubmed_authors><pubmed_authors>Seto AH</pubmed_authors><pubmed_authors>Escaned J</pubmed_authors><pubmed_authors>Walters D</pubmed_authors><pubmed_authors>Lehman SJ</pubmed_authors><pubmed_authors>Going O</pubmed_authors><pubmed_authors>Hellig F</pubmed_authors><pubmed_authors>Vrints CJ</pubmed_authors><pubmed_authors>Samady H</pubmed_authors><pubmed_authors>Indolfi C</pubmed_authors><pubmed_authors>Laine M</pubmed_authors><pubmed_authors>Khashaba A</pubmed_authors><pubmed_authors>Niccoli G</pubmed_authors><pubmed_authors>Dehbi HM</pubmed_authors><pubmed_authors>Bojara W</pubmed_authors><pubmed_authors>Takashima H</pubmed_authors><pubmed_authors>Ribichini F</pubmed_authors><pubmed_authors>Tang K</pubmed_authors><pubmed_authors>Davies JE</pubmed_authors><pubmed_authors>Koo BK</pubmed_authors><pubmed_authors>Patel MR</pubmed_authors><pubmed_authors>Harle T</pubmed_authors><pubmed_authors>Talwar S</pubmed_authors><pubmed_authors>Tanaka N</pubmed_authors><pubmed_authors>Cook CM</pubmed_authors><pubmed_authors>Brugaletta S</pubmed_authors><pubmed_authors>Piek JJ</pubmed_authors><pubmed_authors>Al-Lamee R</pubmed_authors><pubmed_authors>Meuwissen M</pubmed_authors><pubmed_authors>Kharbanda RK</pubmed_authors><pubmed_authors>Kikuta Y</pubmed_authors><pubmed_authors>Alegria-Barrero E</pubmed_authors><pubmed_authors>Buller C</pubmed_authors><pubmed_authors>Gerber RT</pubmed_authors><pubmed_authors>Serruys P</pubmed_authors><pubmed_authors>Doh JH</pubmed_authors><pubmed_authors>Silva PC</pubmed_authors><pubmed_authors>Altman J</pubmed_authors><pubmed_authors>Jeremias A</pubmed_authors><pubmed_authors>Nam CW</pubmed_authors><pubmed_authors>Di Mario C</pubmed_authors><pubmed_authors>Choi KH</pubmed_authors><pubmed_authors>Yokoi H</pubmed_authors><pubmed_authors>Bhindi R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type 2 Diabetes: A Secondary Analysis of a Randomized Clinical Trial.</name><description>&lt;h4>Importance&lt;/h4>Invasive physiologic indices such as fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are used in clinical practice. Nevertheless, comparative prognostic outcomes of iFR-guided and FFR-guided treatment in patients with type 2 diabetes have not yet been fully investigated.&lt;h4>Objective&lt;/h4>To compare 1-year clinical outcomes of iFR-guided or FFR-guided treatment in patients with and without diabetes in the Functional Lesion Assessment of Intermediate Stenosis to Guide Revascularization (DEFINE-FLAIR) trial.&lt;h4>Design, setting, and participants&lt;/h4>The DEFINE-FLAIR trial is a multicenter, international, randomized, double-blinded trial that randomly assigned 2492 patients in a 1:1 ratio to undergo either iFR-guided or FFR-guided coronary revascularizat</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Sep</publication><modification>2026-04-30T03:56:12.215Z</modification><creation>2025-06-01T02:35:45.033Z</creation></dates><accession>S-EPMC6646975</accession><cross_references><pubmed>31314045</pubmed><doi>10.1001/jamacardio.2019.2298</doi></cross_references></HashMap>